Literature DB >> 3815390

Reappraisal of some dosage adjustment guidelines.

A Sulkes, J M Collins.   

Abstract

Mesh：

Substances：

Year:  1987        PMID： 3815390

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

Review 1.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 3.  Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

5.  Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency.

Authors:  R J Motzer; D Niedzwiecki; M Isaacs; C Menendez-Botet; W P Tong; C Flombaum; H I Scher; G J Bosl
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Mitoxantrone use in breast cancer patients with elevated bilirubin.

Authors:  R T Chlebowski; L Bulcavage; I C Henderson; T Woodcock; R Rivest; R Elashoff
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

7.  5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.

Authors:  J Santini; G Milano; A Thyss; N Renee; P Viens; P Ayela; M Schneider; F Demard
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

8.  Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia.

Authors:  Chongyun Xing; Bin Liang; Junqing Wu; Qianqian Yang; Gang Hu; Ye Yan; Yu Zhang; Songfu Jiang; Kang Yu; Jianhua Feng
Journal:  Cancer Manag Res       Date:  2018-03-28       Impact factor: 3.989

9.  Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.

Authors:  Sibylle Schirm; Christoph Engel; Sibylle Loibl; Markus Loeffler; Markus Scholz
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-04       Impact factor: 4.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.